ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026
[Drug resistance characteristics of pulmonary tuberculosis and factors associated with rifampicin resistance in Changsha from 2018 to 2025].
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesDrug-resistant tuberculosis is one of the major challenges currently faced in tuberculosis prevention and control. Regional studies on drug resistance profiles and their influencing factors are of great significance for understanding epidemiological patterns and developing precise prevention and control strategies. This study aims to analyze the drug resistance characteristics and trends of pulmonary tuberculosis in Changsha from 2018 to 2025, and to explore the factors associated with rifampicin (RFP) resistance, so as to provide scientific evidence for precise prevention and control of drug-resistant tuberculosis.
methodsData from 21 351 bacteriologically confirmed pulmonary tuberculosis patients registered in Changsha from 2018 to 2025 were collected from the "China Disease Prevention and Control Information System". The completion of drug resistance screening, mycobacterial species distribution, drug resistance spectrum characteristics, and resistance trends of 5 anti-tuberculosis drugs were analyzed. The Cochran-Armitage trend test was used to compare annual changes, and multivariate Logistic regression analysis was used to identify influencing factors of rifampicin resistance.
resultsFrom 2018 to 2025, the average drug resistance screening rate among bacteriologically confirmed pulmonary tuberculosis patients in Changsha was 90.82%, showing a significant increasing trend (
conclusionsThe drug resistance level of pulmonary tuberculosis in Changsha from 2018 to 2025 was generally stable. However, the RFP resistance rate among new patients was higher than the global and national levels, and the continuous increase in INH resistance rate requires heightened attention. Young and middle-aged adults aged 25-44 years and previously treated patients are high-risk populations for RFP resistance and should be prioritized for drug resistance monitoring and precise intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.